ArticlePloS one2023
Diisocyanates influence models of atopic dermatitis through direct activation of TRPA1.
Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Trial of Cardamom and Topical Roseomonas in Atopic Dermatitis
THREAT: Testing Harms Related to Exposure to Allergenic and Epithelial Toxins
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Wildfires and Atopic Diseases: A Review.Allergy · 2026Review
- P.A.D.D.L.E.: a hypothesis generation tool for assessing pollution's potential role in disease.Scientific reports · 2026Article
- Understanding worldwide skin atopy across regions. Environmental, cultural, genetic, and lifestyle factors.Frontiers in medicine · 2026Review
- Targeting Pollutants in the Treatment and Prevention of Atopic Dermatitis.Immunology and allergy clinics of North America · 2025Review
- The Role of Air Pollution in the Pathogenesis of Atopic Dermatitis, With a Focus on Oxidative Stress.Clinical and translational allergy · 2025Review
- Topical Steroid Withdrawal Is a Targetable Excess of Mitochondrial NAD.The Journal of investigative dermatology · 2025Article
- Environmental and behavioral mitigation strategies for patients with atopic dermatitis.JAAD international · 2024Article
- The clinical, mechanistic, and social impacts of air pollution on atopic dermatitis.The Journal of allergy and clinical immunology · 2024Review
- Derivation of novel metabolic pathway score identifies alanine metabolism as a targetable influencer of TNF-alpha signaling.Heliyon · 2024Article
- Spatial modeling connecting childhood atopic dermatitis prevalence with household exposure to pollutants.Communications medicine · 2024Article
- The circadian metabolome of atopic dermatitis.The Journal of allergy and clinical immunology · 2024Article
- Pharmacologic Inhibition of Transient Receptor Potential Ion Channel Ankyrin 1 Counteracts 2-Chlorobenzalmalononitrile Tear Gas Agent-Induced Cutaneous Injuries.The Journal of pharmacology and experimental therapeutics · 2024Article
- Race science without racists: how bigoted paradigms persist in allergy research.Frontiers in public health · 2024Article
- Antimony Compounds Associate with Atopic Dermatitis and Influence Models of Itch and Dysbiosis.Environmental science & technology letters · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
We recently used EPA databases to identify that isocyanates, most notably toluene diisocyanate (TDI), were the pollutant class with the strongest spatiotemporal and epidemiologic association with atopic dermatitis (AD). Our findings demonstrated that isocyanates like TDI disrupted lipid homeostasis and modeled benefit in commensal bacteria like Roseomonas mucosa through disrupting nitrogen fixation. However, TDI has also been established to activate transient receptor potential ankyrin 1 (TRPA1) in mice and thus could directly contribute to AD through induction of itch, rash, and psychological stress. Using cell culture and mouse models, we now demonstrate that TDI induced skin inflammation in mice as well as calcium influx in human neurons; each of these findings were dependent on TRPA1. Furthermore, TRPA1 blockade synergized with R. mucosa treatment in mice to improve TDI-independent models of AD. Finally, we show that the cellular effects of TRPA1 are related to shifting the balance of the tyrosine metabolites epinephrine and dopamine. This work provides added insight into the potential role, and therapeutic potential, or TRPA1 in the pathogenesis of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.